Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent/assent~* At least 12 years of age at screening~* General good health~* Persistent asthma for ≥3 months, with an FEV1 50-80% predicted and ≥15% reversibility~* Taking inhaled corticosteroids at a stable dose (≤ equivalent of 500mcg of fluticasone propionate/day) for at least 4 weeks prior to the Screening Visit.~* Ability to perform spirometry in an acceptable manner as per protocol guidelines~* Other inclusion criteria apply~Exclusion Criteria:~* A known hypersensitivity to albuterol or any of the excipients in the formulations.~* History of a respiratory infection or disorder that has not resolved within 1 week preceding the Screening Visit (SV).~* History of life-threatening asthma that is defined for this protocol as an asthma episode that required intubation.~* Any asthma exacerbation requiring oral corticosteroids within 3 months of the SV. A subject must not have had any hospitalization for asthma within 6 months prior to the SV.~* Hospitalization due to asthma exacerbation 2 or more times in the past year~* Initiation of immunotherapy or dose escalation during the study period~* Other exclusion criteria apply.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo MDPI (Type: PLACEBO_COMPARATOR): Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks.
- Albuterol MDPI (Type: EXPERIMENTAL): Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).